JP2023554587A5 - - Google Patents

Info

Publication number
JP2023554587A5
JP2023554587A5 JP2023528270A JP2023528270A JP2023554587A5 JP 2023554587 A5 JP2023554587 A5 JP 2023554587A5 JP 2023528270 A JP2023528270 A JP 2023528270A JP 2023528270 A JP2023528270 A JP 2023528270A JP 2023554587 A5 JP2023554587 A5 JP 2023554587A5
Authority
JP
Japan
Prior art keywords
seq
amino acid
fused
antibody
light chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023528270A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023554587A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2021/081303 external-priority patent/WO2022101302A1/en
Publication of JP2023554587A publication Critical patent/JP2023554587A/ja
Publication of JP2023554587A5 publication Critical patent/JP2023554587A5/ja
Pending legal-status Critical Current

Links

JP2023528270A 2020-11-12 2021-11-10 Sars-cov-2 スパイクタンパク質の受容体結合ドメインにコンジュゲートまたは融合している抗体およびワクチン目的でのそれらの使用 Pending JP2023554587A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP20306370.6 2020-11-12
EP20306370 2020-11-12
EP21305091.7 2021-01-26
EP21305091 2021-01-26
PCT/EP2021/081303 WO2022101302A1 (en) 2020-11-12 2021-11-10 Antibodies conjugated or fused to the receptor-binding domain of the sars-cov-2 spike protein and uses thereof for vaccine purposes

Publications (2)

Publication Number Publication Date
JP2023554587A JP2023554587A (ja) 2023-12-28
JP2023554587A5 true JP2023554587A5 (cg-RX-API-DMAC7.html) 2024-09-09

Family

ID=78599029

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023528270A Pending JP2023554587A (ja) 2020-11-12 2021-11-10 Sars-cov-2 スパイクタンパク質の受容体結合ドメインにコンジュゲートまたは融合している抗体およびワクチン目的でのそれらの使用

Country Status (8)

Country Link
US (1) US20240010739A1 (cg-RX-API-DMAC7.html)
EP (1) EP4244253A1 (cg-RX-API-DMAC7.html)
JP (1) JP2023554587A (cg-RX-API-DMAC7.html)
KR (1) KR20230107260A (cg-RX-API-DMAC7.html)
CA (1) CA3200878A1 (cg-RX-API-DMAC7.html)
CO (1) CO2023007284A2 (cg-RX-API-DMAC7.html)
MX (1) MX2023005570A (cg-RX-API-DMAC7.html)
WO (1) WO2022101302A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU20210070A7 (es) * 2021-08-20 2023-03-07 Ct Ingenieria Genetica Biotecnologia Antígenos quiméricos para el control de coronavirus y composiciones que los comprenden
WO2024004159A1 (ja) * 2022-06-30 2024-01-04 Eps創薬株式会社 舌下投与用ワクチン組成物

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4861719A (en) 1986-04-25 1989-08-29 Fred Hutchinson Cancer Research Center DNA constructs for retrovirus packaging cell lines
US5278056A (en) 1988-02-05 1994-01-11 The Trustees Of Columbia University In The City Of New York Retroviral packaging cell lines and process of using same
WO1989012624A2 (en) 1988-06-14 1989-12-28 Cetus Corporation Coupling agents and sterically hindered disulfide linked conjugates prepared therefrom
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5670488A (en) 1992-12-03 1997-09-23 Genzyme Corporation Adenovirus vector for gene therapy
JP3866760B2 (ja) 1993-02-22 2007-01-10 ザ ロックフェラー ユニバーシティ 一過性トランスフェクションによる高力価のヘルパーフリーのレトロウイルスの生産
FR2712812B1 (fr) 1993-11-23 1996-02-09 Centre Nat Rech Scient Composition pour la production de produits thérapeutiques in vivo.
IL116816A (en) 1995-01-20 2003-05-29 Rhone Poulenc Rorer Sa Cell for the production of a defective recombinant adenovirus or an adeno-associated virus and the various uses thereof
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
DE60131456T2 (de) 2000-11-30 2008-07-10 Medarex, Inc., Milpitas Transchromosomale transgen-nagetiere zur herstellung von humanen antikörpern
AR039067A1 (es) 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
ES2367430T3 (es) 2002-12-23 2011-11-03 Wyeth Llc Anticuerpos contra pd-1 y sus usos.
EP3530736A3 (en) 2005-05-09 2019-11-06 ONO Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
KR101704734B1 (ko) 2005-07-01 2017-02-09 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체
EP2684889A3 (en) 2007-02-02 2014-03-05 Baylor Research Institute Multivariable antigens complexed with targeting humanized monoclonal antibody
PT2242773T (pt) 2008-02-11 2017-09-15 Cure Tech Ltd Anticorpos monoclonais para o tratamento de tumores
US8168757B2 (en) 2008-03-12 2012-05-01 Merck Sharp & Dohme Corp. PD-1 binding proteins
WO2010009346A2 (en) 2008-07-16 2010-01-21 Baylor Research Institute Hiv vaccine based on targeting maximized gag and nef to dendritic cells
WO2010098788A2 (en) 2008-08-25 2010-09-02 Amplimmune, Inc. Pd-i antagonists and methods for treating infectious disease
EA201500417A1 (ru) 2008-08-25 2015-11-30 Эмплиммьюн, Инк. Композиции антагонистов pd-1 и способы применения
MX356367B (es) 2008-12-09 2018-05-25 Genentech Inc Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t.
BRPI1009454A2 (pt) * 2009-03-10 2019-09-24 Baylor Res Institute vacinas contra o câncer direcionadas a células apresentadoras de antígenos
US8345509B2 (en) 2009-04-16 2013-01-01 Chevron U.S.A., Inc. System and method to create three-dimensional images of non-linear acoustic properties in a region remote from a borehole
WO2011032161A2 (en) 2009-09-14 2011-03-17 Baylor Research Institute Vaccines directed to langerhans cells
EP3279215B1 (en) 2009-11-24 2020-02-12 MedImmune Limited Targeted binding agents against b7-h1
EP2504028A4 (en) 2009-11-24 2014-04-09 Amplimmune Inc SIMULTANEOUS INHIBITION OF PD-L1 / PD-L2
KR20130108295A (ko) 2010-08-13 2013-10-02 베일러 리서치 인스티튜트 항원-제시 세포에 항체에 대한 보조제를 직접 표적화함을 기초로 하는 신규 백신 보조제
CA2813411C (en) 2010-11-05 2016-08-02 Rinat Neuroscience Corporation Engineered polypeptide conjugates and methods for making thereof using transglutaminase
BR112014012819B1 (pt) 2011-11-28 2022-08-16 Merck Patent Gmbh Anticorpo anti-pd-l1 ou fragmento de ligação ao antígeno do mesmo e composição
RS57508B1 (sr) 2013-09-06 2018-10-31 Aurigene Discovery Tech Ltd 1,2,4-derivati oksadiazola kao imunomodulatori
TR201811077T4 (tr) 2013-09-06 2018-08-27 Aurigene Discovery Tech Ltd İmmünomodülatörler olarak 1,3,4-oksadiazol ve 1,3,4-tiyadiyazol türevleri.
US10610585B2 (en) * 2017-09-26 2020-04-07 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and compositions for treating and preventing HIV
CN111217917B (zh) * 2020-02-26 2020-10-23 康希诺生物股份公司 一种新型冠状病毒SARS-CoV-2疫苗及其制备方法
CN111533809A (zh) * 2020-04-21 2020-08-14 中国科学院武汉病毒研究所 针对新型冠状病毒的亚单位疫苗及应用

Similar Documents

Publication Publication Date Title
JP2023528017A5 (cg-RX-API-DMAC7.html)
AU2004279877B2 (en) Fully human antibodies against human 4-1BB (CD137)
JP5363432B2 (ja) 樹状細胞−t細胞の相互作用を調節するための組成物及び方法
EP2406286B1 (en) Anti-cd40 antibodies and uses thereof
US7563445B2 (en) CD40 binding molecules and CTL peptides for treating tumors
CN105884903B (zh) 靶向抗原呈递细胞的疫苗
EP1434596B1 (en) Enhancement of immune responses by agonist 4-1bb-antibodies
EP3138854B1 (en) Antibodies against cd40
KR20130036246A (ko) 사람 cd8+ t 세포의 수지상 세포 면역수용체(dcir)-매개 교차프라이밍
TW200902061A (en) Vaccines based on targeting antigen to DCIR expressed on antigen-presenting cells
EP1599504A1 (en) Modified antibody
KR20090114466A (ko) 덱틴-1을 통한 사람 항원제시세포 활성화의 치료학적 적용
KR20090127886A (ko) 수지상 세포 렉틴 유사 산화된 ldl 수용체-1(lox-1)을 통한 사람 항원제시세포의 활성화
KR20090118981A (ko) Clec-6을 통한 사람 항원제시세포의 활성화
Tunheim et al. Human receptors of innate immunity (CD14, TLR2) are promising targets for novel recombinant immunoglobulin-based vaccine candidates
HK1227905A1 (en) Antigen presenting cell targeted vaccines
HK1227905A (en) Antigen presenting cell targeted vaccines
HK1178546A (en) Antigen presenting cell targeted vaccines